Table 2.
Patients’ demographic characteristics, comorbidities and treatments they received
|
|
Total, n = 85
|
Group 1, n = 43
|
Group 2, n = 42
|
P
value
|
| Age (mean ± SD) | 43.6 ± 13.0 | 43.6 ± 12.2 | 43.6 ± 14.0 | 0.888 |
| Gender, n (%) | ||||
| Female | 62 (72.9) | 33 (76.7) | 29 (69.0) | 0.425 |
| Male | 23 (27.1) | 10 (23.3) | 13 (31.0) | |
| Employment status, n (%) | ||||
| No | 49 (57.6) | 25 (58.1) | 24 (57.1) | 0.926 |
| Yes | 36 (42.4) | 18 (41.9) | 18 (42.9) | |
| Comorbid diseases | ||||
| Hashimoto’s thyroiditis, n (%) | ||||
| No | 67 (78.8) | 36 (83.7) | 31 (73.8) | 0.263 |
| Yes | 18 (21.2) | 7 (16.3) | 11 (26.2) | |
| Allergic asthma, n (%) | ||||
| No | 77 (90.6) | 36 (83.7) | 41 (97.6) | 0.058 |
| Yes | 8 (9.4) | 7 (16.3) | 1 (2.4) | |
| Hypertension, n (%) | ||||
| No | 72 (84.7) | 38 (88.4) | 34 (81.0) | 0.342 |
| Yes | 13 (15.3) | 5 (11.6) | 8 (19.0) | |
| Gastritis, n (%) | ||||
| No | 77 (90.6) | 37 (86.0) | 40 (95.2) | 0.265 |
| Yes | 8 (9.4) | 6 (14.0) | 2 (4.8) | |
| Hyperlipidemia, n (%) | ||||
| No | 78 (91.8) | 40 (93.0) | 38 (90.5) | 0.713 |
| Yes | 7 (8.2) | 3 (7.0) | 4 (9.5) | |
| Depression, n (%) | ||||
| No | 80 (94.1) | 41 (95.3) | 39 (92.9) | 0.676 |
| Yes | 5 (5.9) | 2 (4.7) | 3 (7.1) | |
| Comorbidity, n (%) | ||||
| No | 26 (30.6) | 12 (27.9) | 14 (33.3) | 0.587 |
| Yes | 59 (69.4) | 31 (72.1) | 28 (66.7) | |
| Abdominal surgery, n (%) | ||||
| No | 50 (58.8) | 24 (55.8) | 26 (61.9) | 0.568 |
| Yes | 35 (41.2) | 19 (44.2) | 16 (38.1) | |
| Drug use | ||||
| Systematic drug use, n (%) | ||||
| No | 28 (32.9) | 14 (32.6) | 14 (33.3) | 0.939 |
| Yes | 57 (67.1) | 29 (67.4) | 28 (66.7) | |
| PPI use, n (%) | ||||
| No | 67 (78.8) | 32 (74.4) | 35 (83.3) | 0.315 |
| Yes | 18 (21.2) | 11 (25.6) | 7 (16.7) | |
| Psychiatric drug use, n (%) | ||||
| No | 71 (83.5) | 34 (79.1) | 37 (88.1) | 0.262 |
| Yes | 14 (16.5) | 9 (20.9) | 5 (11.9) | |
| CCB use, n (%) | ||||
| No | 69 (81.2) | 36 (83.7) | 33 (78.6) | 0.544 |
| Yes | 16 (18.8) | 7 (16.3) | 9 (21.4) | |
| Beta-blocker use, n (%) | ||||
| No | 75 (88.2) | 38 (88.4) | 37 (88.1) | > 0.999 |
| Yes | 10 (11.8) | 5 (11.6) | 5 (11.9) | |
Group 1: Low fermentable oligo, di- and monosaccharides and polyol diet + probiotic; Group 2: Low fermentable oligo, di- and monosaccharides and polyol diet + placebo. PPI: Proton pump inhibitor; CCB: Calcium canal blocker; SD: Standard deviation.